Laryngeal edema following remimazolam-induced anaphylaxis: a rare clinical manifestation

BMC Anesthesiol. 2023 Mar 29;23(1):99. doi: 10.1186/s12871-023-02052-w.

Abstract

Background: Remimazolam is an ultra-short-acting intravenous benzodiazepine, which has been used as sedative/anesthetic in procedural sedation and anesthesia. Although peri-operative anaphylaxis due to remimazolam has been reported recently, the spectrum of the allergic reactions is still not fully known.

Case presentation: We describe a case of anaphylaxis following remimazolam administration in a male patient undergoing colonoscopy under procedural sedation. The patient presented complex clinical signs including airway changes, skin symptoms, gastrointestinal manifestations and hemodynamic fluctuations. Different from other reported cases, laryngeal edema was the initial and main clinical feature of remimiazolam-induced anaphylaxis.

Conclusions: Remimazolam-induced anaphylaxis has a rapid onset and complex clinical features. This case reminds anesthesiologists should be particularly alert to the unknown adverse reactions of new anesthetics.

Keywords: Anaphylaxis; Remimazolam; Sedation.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anaphylaxis* / chemically induced
  • Anaphylaxis* / diagnosis
  • Benzodiazepines* / adverse effects
  • Humans
  • Hypnotics and Sedatives / adverse effects
  • Laryngeal Edema* / chemically induced
  • Laryngeal Edema* / drug therapy
  • Male

Substances

  • Benzodiazepines
  • Hypnotics and Sedatives
  • remimazolam